Introduction {#s1}
============

Measles remains an important cause of death among under-five children ([@bib29]). Much of this persisting global burden of measles is located in Africa and Asia, notably in India ([@bib4]; [@bib8]). Direct estimation of cause-specific mortality documented a 90% decline in 1--59 month measles mortality rates in India from 2000 to 2015 ([@bib9]).

The role of national intervention strategies in explaining the decline in measles deaths in India is unknown. In 2005, the Government of India launched the National Rural Health Mission -- a program geared towards improving public health infrastructure and reducing child mortality in priority states ([@bib26]). In 2008, the Government of India announced a policy change to introduce second-dose measles vaccine through the routine immunization ([@bib27]). District-level mass immunization campaigns (termed supplementary immunization activities) for second-dose measles vaccine were launched in 2010 in 14 target states where first-dose measles vaccination coverage was below 80% (hereafter referred to as campaign states). The campaign prioritized immunization of children aged 9 months to 10 years in the 14 campaign states, after which second-dose measles vaccine was provided through routine immunization. The remaining 21 states with higher coverage added only second-dose measles vaccine through routine immunization ([@bib14]).

The ideal method of evaluation, a randomized trial, was not practical in the rollout of the national campaign. Mathematical models estimate an 84% decline in measles deaths globally during 2000--2016, but are unable to evaluate the effectiveness of interventions ([@bib8]; [@bib20]). In these scenarios, interrupted time series is considered a robust quasi-experimental evaluation method ([@bib6]). Here, we apply interrupted time series supplemented with multilevel regression analysis to provide the first direct quantification of the impact of the national mass measles immunization campaign on childhood measles mortality in India. These analyses have the additional advantage of using the Million Death Study (MDS), a nationally representative sample of all deaths in India, including 27,000 child deaths from 1.3 million households surveyed from 2005 to 2013 ([@bib9]; [@bib11]).

Results {#s2}
=======

Characteristics of subjects {#s2-1}
---------------------------

From 2005 to 2013, the MDS captured deaths for 13,490 girls and 13,007 boys aged 1--59 months after excluding children missing cause of death (2.8%). Of the 1,638 measles deaths using the definition of one or more physician coding or the family reported a measles history for the deceased, 79% occurred in rural areas, 73% in campaign states, 59% at ages 12--59 months, and 57% in girls ([Table 1](#table1){ref-type="table"}). 76% of families reporting a measles death noted the child to have a history of measles (using the local language term), but only 39% of the deceased children received at least one dose of measles vaccine. The proportion of measles deaths at 1--59 months in campaign states reporting at least one dose of measles vaccine rose modestly (34% to 47%) from 2005--2009 to 2010--2013, but was mostly unchanged in non-campaign states (48% to 51%). Despite inherent misclassification that can be expected from verbal autopsies, we observed that the proportion vaccinated against measles did not differ across case definitions, suggesting that physician assignment of deaths was not unduly biased by a history of measles vaccination ([Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}).
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###### Measles deaths among 1--59-month children by campaign states, India, 2005--2013.

10.7554/eLife.43290.004Table 1---source data 1.Sample characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Child Characteristics                               Campaign States (n = 1,195)   Non-campaign States (n = 443)                                               
  --------------------------------------------------- ----------------------------- ------------------------------- ---------------- ------------------ ------- ----------------
                                                      **Study Deaths**              **%**                           **Crude OR**\    **Study Deaths**   **%**   **Crude OR**\
                                                                                                                    **(95% CI)**                                **(95% CI)**

  **Age Groups**                                                                                                                                                

  1 to 11 Months                                      374/68                        36/33                           Ref              159/63             49/48   Ref

  12 to 59 Months                                     627/126                       64/67                           1.6 (1.5, 1.9)   151/70             51/52   1.3 (1.0, 1.5)

  **Sex**                                                                                                                                                       

  Male                                                415/86                        41/41                           Ref              142/54             45/43   Ref

  Female                                              586/108                       59/59                           1.1 (0.8, 1.6)   168/79             55/57   1.2 (0.8, 1.9)

  **Residence**                                                                                                                                                 

  Urban                                               116/30                        12/14                           Ref              69/28              33/29   Ref

  Rural                                               885/164                       88/86                           0.7 (0.5, 1.1)   241/105            67/71   1.1 (0.6, 1.8)

  **National Health Mission (NHM)**                                                                                                                             

  Other States                                        148/35                        8/11                            Ref              211/99             77/81   Ref

  NHM States                                          853/159                       92/89                           0.8 (0.5, 1.2)   99/34              23/19   0.7 (0.4, 1.2)

  **Empowered Action Group (EAG)**                                                                                                                              

  Richer States                                       195/46                        9/11                            Ref              236/105            80/83   Ref

  Poorer States                                       806/148                       91/89                           0.8 (0.5, 1.1)   74/28              20/17   0.9 (0.5, 1.4)

  **Family Reported Child**\                                                                                                                                    
  **Had History of Measles^†^**                                                                                                                                 

  Yes                                                 783/132                       79/64                           3.0 (1.7, 5.1)   235/101            76/76   0.7 (0.2, 1.8)

  No                                                  48/24                         4/13                            Ref              23/7               7/5     Ref

  Missing                                             170/38                        17/23                                            52/25              17/19   

  **Child Received ≥ 1 Dose of Measles Vaccine^‡^**                                                                                                             

  Yes                                                 346/91                        34/47                           0.4 (0.3, 0.6)   144/66             48/51   0.9 (0.6, 1.5)

  No                                                  509/75                        51/38                           Ref              125/54             39/40   Ref

  Missing                                             146/28                        15/15                                            41/13              13/9    

  **History of Rash**                                                                                                                                           

  Yes                                                 866/159                       86/78                           1.4 (0.9, 2.1)   275/119            87/89   1.1 (0.5, 2.2)

  No                                                  126/32                        13/21                           Ref              30/14              11/11   Ref

  Missing                                             9/3                           1/1                                              5/0                2/0     

  **History of Fever**                                                                                                                                          

  Yes                                                 761/135                       75/69                           1.2 (0.8, 1.8)   214/98             72/74   0.7 (0.4, 1.2)

  No                                                  209/46                        22/24                           Ref              84/28              25/21   Ref

  Missing                                             31/13                         3/7                                              12/7               3/5     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The measles case definition attributed a death to measles if at least one physician assigned measles as the cause of death or if the respondent reported the deceased child to have a history of measles (using the local language term).

^†^ Respondents were asked whether the child had any skin diseases or rash, followed by whether this was measles using the local term.

^‡^ Respondents were asked whether the child was immunized and, if so, whether they received an injection for measles using the local term.

Annual measles deaths at ages 1--59 months fell from 62,000 to 24,000 from 2005 to 2013 ([Figure 1](#fig1){ref-type="fig"}). Prior to campaign launch, 76% of measles deaths were concentrated in campaign states, 55% of which were in the states of Uttar Pradesh (18%), Madhya Pradesh (15%), Rajasthan (11%), and Bihar (11%). Following campaign launch, 59% of measles deaths were in campaign states, with 38% in the above four states ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The age distributions did not differ greatly between pre-campaign and post-campaign periods ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The 1--59 month measles mortality rate per thousand live births declined substantially during this period. The average annual rate reduction (AARR) in measles mortality over the full study period was 12% but accelerated to 22% following campaign launch. Post-campaign declines in measles mortality were faster in the campaign states (27%) versus non-campaign states (11%). The AARR declined most notably in campaign states (15%) and in the states of Madhya Pradesh (20%), Uttar Pradesh (19%), Rajasthan (17%), Chhattisgarh (17%), and Gujarat (14%) ([Table 2](#table2){ref-type="table"}).

![Measles mortality rates and average annual rate reduction among 1--59 month-old children by sex, campaign states, and residence, India, 2005--2013.\
The measles case definition attributed a death to measles if at least one physician assigned measles as the cause of death or if the respondent reported the deceased child to have a history of measles (using the local language term). Mortality rates were calculated using 3 year moving averages of weighted proportions applied to UN deaths and live births estimates for India. Campaign states include: Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Gujarat, Haryana, Jharkhand, Madhya Pradesh, Manipur, Meghalaya, Nagaland, Rajasthan, Tripura, and Uttar Pradesh. Non-campaign states include all other states and union territories. \* indicates the year 2010. PRE = average annual rate reduction pre-intervention. POST = average annual rate reduction post-intervention. AARR = average annual rate reduction overall.\
10.7554/eLife.43290.009Figure 1---source data 1.Child measles mortality rates.](elife-43290-fig1){#fig1}
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###### Average annual rate reduction of 1--59-month measles mortality by measles campaign states versus non-campaign states, big states in India, 2005--2013.

10.7554/eLife.43290.011Table 2---source data 1.Average annual rate reduction of measles mortality.

  Big States in India       AARR (95% CI)
  ------------------------- ----------------------
  **Campaign States**       **14.6 (5.3, 23.0)**
  Assam                     1.7 (--0.6, 3.9)
  Bihar                     12.2 (--1.5, 24.1)
  Chhattisgarh              16.9 (1.0, 30.3)
  Gujarat                   13.6 (1.2, 24.4)
  Haryana                   2.8 (--3.3, 8.5)
  Jharkhand                 8.2 (--24.9, 32.4)
  Madhya Pradesh            19.9 (6.6, 31.3)
  Rajasthan                 16.8 (4.6, 27.3)
  Uttar Pradesh             18.8 (14.5, 22.8)
  **Non-Campaign States**   **6.8 (3.8, 9.7)**
  Andhra Pradesh            12.9 (0.3, 24.0)
  Himachal Pradesh          --7.7 (--32.8, 12.7)
  Jammu and Kashmir         2.6 (--3.4, 8.2)
  Karnataka                 16.2 (7.9, 23.8)
  Maharashtra               --3.3 (--13.8, 6.2)
  Odisha                    6.0 (--0.8, 12.4)
  Punjab                    7.5 (--0.6, 14.9)
  Tamil Nadu                6.2 (--2.5, 14.2)
  Uttarakhand               7.9 (--13.1, 25.0)
  West Bengal               7.5 (2.7, 12.1)
  **India (Overall)**       **12.2 (4.7, 19.0)**

AARR = average annual rate reduction. States with AARR containing zero in the 95% confidence interval were considered to have no significant change in AARR of measles mortality. In campaign states, the pre-intervention AARR is −4.0% (-42.0%, 24.0%) and the post-intervention AARR is 26.8% (-1.1%, 47.0%). In non-campaign states, the pre-intervention AARR is 1.4% (-18.6%, 18.1%) and the post-intervention AARR is 10.6% (2.5%, 18.1%).

Interrupted time series analysis {#s2-2}
--------------------------------

Measles mortality rates among 1--59 month-old children in campaign states declined significantly following campaign launch ([Figure 2](#fig2){ref-type="fig"}) when compared to control deaths from injuries, congenital anomalies, and non-communicable diseases of the same ages. There were no other mass public health interventions targeting this age group during the study period. The choice of control deaths is unbiased as these conditions are unaffected by measles vaccination and provide pre-intervention trends comparable to trends of measles deaths from 2005 to 2009. As well, cases and controls deaths were sampled with the same method and assigned a cause of death by two independent physicians. We noted a temporary increase in measles mortality in 2009. This might reflect increased reporting as this was also the period when measles surveillance expanded. Thus, we used 2009 as the intervention year to account for the increased reporting.

![Interrupted time-series analysis on measles, pneumonia, and diarrhoea mortality (black) and control mortality (white) among 1--59 month-old children during the measles campaign in India, 2005--2013.\
Refer to [Figure 1](#fig1){ref-type="fig"} for the definition of measles deaths. Control deaths were selected based on comparability of their pre-intervention trends to trends for measles. For measles in campaign states and non-campaign states, control deaths were injuries, non-communicable diseases, or congenital anomalies. For pneumonia (n = 4,403) and diarrhoea (n = 3,468) deaths in campaign states, control deaths were non-communicable diseases or congenital anomalies. Difference in slope represents the difference in pre-post trends between the measles and control deaths. Difference in level represents the difference between the level of measles and control mortality rates immediately following campaign launch. We observed no significant difference when comparing pre-intervention trends for the control deaths to the deaths from measles, pneumonia, or diarrhoea in the campaign states, or to measles deaths in the non-campaign states (p\>0.1 for all four comparisons).\
10.7554/eLife.43290.013Figure 2---source data 1.Child measles, pneumonia, and diarrhoea mortality rates in campaign states.](elife-43290-fig2){#fig2}

The interrupted time series analyzes changes in the *slope* of six-month measles mortality rate per thousand live births and changes in the *level* (which were few). Prior to campaign launch, the slope of measles mortality in campaign states remained unchanged at --0.004 deaths per thousand live births (95% CI --0.065, 0.056; [Table 3](#table3){ref-type="table"}). The control deaths also remained unchanged with an analogous slope of 0.003 (95% CI --0.054, 0.062). Following campaign launch, the slope of measles mortality in campaign states fell significantly to --0.164 (95% CI --0.320, --0.008, p=0.040), whereas the slope for the control deaths remained unchanged. Declines in measles mortality in India overall were similar to declines in campaign states (--0.132, 95% CI --0.252, --0.011, p=0.034; [Figure 3](#fig3){ref-type="fig"}). In comparison, non-campaign states saw no significant change in measles mortality rates following campaign launch. Notably, the rate ratio of 1--59 month measles mortality between campaign states and non-campaign states fell from 3.1 to 1.8 during 2005--2013. The declines were specific to measles deaths, as we observed no significant changes in slope for pneumonia and diarrhoea deaths following campaign launch.

![Stratified analysis of interrupted time-series models on measles mortality (black) versus control mortality (white) among 1--59 month-old children, India.\
The measles case definition attributed a death to measles if at least one physician assigned measles as the cause of death or if the respondent reported the deceased child to have a history of measles (using the local language term). Control deaths were selected based on comparability of pre-intervention trends to trends for measles. Control deaths were injuries, non-communicable diseases, or congenital anomalies.\
10.7554/eLife.43290.015Figure 3---source data 1.Child measles mortality rates in campaign states by age and sex.](elife-43290-fig3){#fig3}
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###### Changes in slope and level of measles mortality log rates before and after campaign launch, India, 2005--2013.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Change in slope before campaign launch   Change in slope after campaign launch   Adjusted change in level   Adjusted change in slope    P-value\
                                                                                                                                                                    of adjusted\
                                                                                                                                                                    change in\
                                                                                                                                                                    slope
  ------------------------- ---------------------------------------- --------------------------------------- -------------------------- --------------------------- --------------
  **India**                 --0.009 (--0.056, 0.038)                 --0.125 (--0.251, 0.001)                0.165 (--0.405, 0.736)     --0.132 (--0.252,--0.011)   0.034

  **Girls**                 --0.005 (--0.298, 0.684)                 --0.135 (--0.240,--0.031)               0.204 (--0.291, 0.700)     --0.135 (--0.227,--0.043)   0.006

  **Boys**                  --0.014 (--0.071, 0.044)                 --0.112 (--0.272, 0.049)                0.058 (--0.673, 0.788)     --0.125 (--0.278, 0.029)    0.107

  **12-to-59-months**       --0.011 (--0.060, 0.038)                 --0.124 (--0.243,--0.024)               0.148 (--0.288, 0.584)     --0.139 (--0.235,--0.043)   0.006

  **1-to-11-months**        0.001 (--0.042, 0.044)                   --0.129 (--0.296, 0.038)                0.162 (--0.653, 0.977)     --0.127 (--0.287, 0.032)    0.113

  **Campaign States**       --0.004 (--0.065, 0.056)                 --0.157 (--0.320, 0.007)                0.121 (--0.592, 0.835)     --0.164 (--0.320,--0.008)   0.040

  **Girls**                 --0.004 (--0.062, 0.053)                 --0.178 (--0.330,--0.025)               0.256 (--0.362, 0.873)     --0.177 (--0.307,--0.047)   0.019

  **Boys**                  --0.002 (--0.083, 0.079)                 --0.137 (--0.331, 0.057)                --0.023 (--0.915, 0.870)   --0.150 (--0.336, 0.036)    0.109

  **12-to-59-months**       --0.010 (--0.070, 0.051)                 --0.161 (--0.306,--0.016)               0.166 (--0.432, 0.763)     --0.175 (--0.314,--0.036)   0.015

  **1-to-11-months**        0.011 (--0.048, 0.069)                   --0.152 (--0.361, 0.058)                --0.001 (--0.355, 0.046)   --0.155 (--0.355, 0.046)    0.125

  **Non-campaign States**   --0.027 (--0.041,--0.014)                --0.040 (--0.090, 0.010)                0.193 (--0.094, 0.481)     --0.037 (--0.088, 0.015)    0.157
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are ordinary least-squares regression models adjusted for time fixed effects and time interactions. Estimates are given with 95% confidence intervals. Refer to [Figure 2](#fig2){ref-type="fig"} and [Table 5](#table5){ref-type="table"} for the description of measles and control deaths definition. Campaign states include: Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Gujarat, Haryana, Jharkhand, Madhya Pradesh, Manipur, Meghalaya, Nagaland, Rajasthan, Tripura, and Uttar Pradesh. Non-campaign states include all other states and union territories. For India and campaign states, change in slope is adjusted for trends in control conditions of injuries, non-communicable diseases, or congenital anomalies. Control groups are selected based on comparison of pre-intervention trends for each non-measles cause of death to that of measles and selecting those groups who show no significant change in pre-intervention slope. The adjusted change in level represents the difference in the level between measles and control in the six months immediately following campaign launch. The adjusted change in slope is a difference-in-difference slope representing the difference between the treatment and control group\'s differences in their pre-intervention and post-intervention trends.

Following campaign launch, we observed sharper declines in measles mortality rates among campaign states compared to non-campaign states ([Figure 3](#fig3){ref-type="fig"}). Girls residing in campaign states saw steeper declines in measles mortality relative to boys, even though the direction of effect was similar in both sexes. Additional stratified analyses yielded generally similar results. In campaign states, the decline in measles mortality was significant at 12--59 months but not significant at 1--11 months. At ages 1--59 months, alternative definitions of measles cases, using one or both physicians assigning measles as the underlying cause of death, also yielded similar results ([Figure 4](#fig4){ref-type="fig"}). We observed a significant change in slope and level in campaign states when two physicians agreed immediately or when one physician assigned measles as the cause of death (both definitions excluded a family reported history of measles which might have been affected by publicity for the campaign). Moving the intervention year forward to 2010 resulted in the *slope* of measles mortality following campaign launch becoming non-significant (--0.01, 95% CI --0.08, 0.05). However, we observed a significant decrease in *level* of measles mortality following campaign launch (--1.05, 95% CI --1.50, --0.61). In all other stratified analyses, we observed no significant change in level ([Table 3](#table3){ref-type="table"}).

![Interrupted time-series models on measles mortality (black) versus control mortality (white) among 1--59 month-old children using alternate measles definitions, India.\
We present two narrower measles definitions of one or more physician coding and both physician coding of measles. All other control deaths were injuries, non-communicable diseases, or congenital anomalies. Control deaths were selected based on comparability of pre-intervention trends to trends for measles. For both physicians and at least one physician coding measles, control deaths were congenital anomalies or non-communicable diseases. We observed no significant difference when comparing pre-intervention trends for the control deaths to those for case deaths based on the narrower definitions of at least one physician coding measles and both physicians coding measles (p\>0.4 for both comparisons).\
10.7554/eLife.43290.018Figure 4---source data 1.Child measles mortality rates by case definition.](elife-43290-fig4){#fig4}

Coverage of measles immunization and related health indicators {#s2-3}
--------------------------------------------------------------

National measles immunization coverage (defined as the percentage of children aged 12 to 23 months receiving any dose of measles vaccine from routine immunization) improved from 2002 to 2014, particularly in campaign states ([Figure 5](#fig5){ref-type="fig"}). In difference-in-difference analysis, we observed a significant increase in measles vaccination coverage in the campaign states relative to non-campaign states, concurrent with campaign launch (difference-in-difference estimate 16.9%, p=0.0000009). Other coverage indicators, such as vitamin A supplementation, pneumonia treatment-seeking, oral rehydration, maternal literacy, and diarrhoea treatment-seeking showed significant increases over time, but these increases did not differ significantly between campaign and other states ([Figure 5](#fig5){ref-type="fig"}).

![National coverage estimates of child immunization, maternal literacy, and oral rehydration supplementation by measles campaign states, India, 2005--2013.\
Estimates were obtained from the National Family Health Survey and the District Level Household and Facility Survey through 2002 to 2014. Measles vaccination coverage was defined as the percentage of children aged 12 to 23 months receiving any measles vaccine from routine immunization. The difference-in-difference test reports the change in coverage estimates before and after campaign launch in campaign states versus non-campaign states. We observed no significant change in coverage estimates between campaign states versus non-campaign states for maternal literacy and diarrhoea treatment-seeking (data not shown).](elife-43290-fig5){#fig5}

Multilevel logistic regression analysis {#s2-4}
---------------------------------------

Among 26,505 overall child deaths at 1--59 months for the whole of India from 2005 to 2013, the odds of measles mortality were higher at 12--59 months (OR 1.5, 99% CI 1.3--1.7) than at ages 1--11 months, after adjusting for covariates identified in the above difference-in-difference analyses ([Figure 6](#fig6){ref-type="fig"}). Children born in 2009 or later were at lower odds of measles mortality compared with earlier births (OR 0.8, 99% CI 0.7--0.9). Children living in districts within campaign states had lower odds of measles mortality (OR 0.6, 99% CI 0.4--0.8) than children living in non-campaign states. Girls had higher odds of measles mortality (OR 1.3, 99% CI 1.1--1.5) than boys. Consistent with this finding, girls had higher excess measles mortality risk relative to all-cause mortality in campaign states than boys, and the excess risk was distributed far more widely in girls than boys in these states ([Figure 7](#fig7){ref-type="fig"}).

![Multilevel logistic regression analysis of measles mortality among 1--59 month children, India, 2005--2013.\
N = number of observations; n = number of measles deaths. Living in a campaign district was assigned based on the individual's date of birth and the month when a particular district launched campaigns. The models were fitted with random intercepts by state and district and were adjusted for urban/rural residence, measles vaccination coverage, vitamin A supplementation, oral rehydration supplementation, maternal literacy, pneumonia treatment-seeking, and diarrhoea treatment-seeking. Effect estimates are weighted by their inverse-variance. There was significant variation in measles mortality odds across districts (τ = 0.094) and across states (τ = 0.147). Residual heterogeneity between regions remained significant after adjustment -- the median odds ratio was 1.28 at the district level and 1.43 at the state level, while the intra-class correlation was 6.8% at the district level and 4.2% at the state level.](elife-43290-fig6){#fig6}

![Distribution of 1--59 month measles mortality risk (relative to all-cause mortality) by sex, India, 2005--2013.\
We fitted maps using a generalized linear geostatistical model with integrated nested Laplace approximations adjusted for children living in campaign districts and urban/rural residence. \* denotes campaign states. AN = Andaman and Nicobar Islands. AP = Andhra Pradesh. AR\* = Arunachal Pradesh. AS\* = Assam. BR\* = Bihar. CH = Chandigarh. CG\* = Chhattisgarh. DD = Daman and Diu. DN = Dadra and Nagar Haveli. DL = Delhi. GA = Goa. GJ\* = Gujarat. HP = Himachal Pradesh. HR\* = Haryana. JH\* = Jharkhand. JK = Jammu and Kashmir. KA = Karnataka. KL = Kerala. LD = Lakshadweep. MH = Maharashtra. ML\* = Meghalaya. MN\* = Manipur. MP\* = Madhya Pradesh. MZ = Mizoram. NL\* = Nagaland. OD = Odisha. PB = Punjab. PY = Puducherry. RJ\* = Rajasthan. SK = Sikkim. TN = Tamil Nadu. TR\* = Tripura. UP\* = Uttar Pradesh. UT = Uttarakhand. WB = West Bengal. Refer to [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for the description of NHM and EAG states.](elife-43290-fig7){#fig7}

Mortality impact {#s2-5}
----------------

Conservatively, we estimate that the national campaign averted 41,000 to 56,000 (median 48,500) child deaths in India during 2010--2013 ([Table 4](#table4){ref-type="table"}). The majority of deaths averted were in campaign states (median 41,000) with a similar number of deaths averted among girls (median 18,500) and boys (median 22,500) in these states. For India as a whole, the averted measles deaths comprise 39--57% of the expected measles deaths during 2010--2013.

10.7554/eLife.43290.022

###### Deaths averted among 1--59-month-old children following measles campaign launch, India.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Expected 2013 rate per 1,000 live births   Observed 2013 rate per 1,000 live births   Deaths without intervention,\   Deaths averted, 2010- 2013 (000s)   Percent averted (%)
                                                                                                                  2010--2013 (000 s)                                                  
  ------------------------- ------------------------------------------ ------------------------------------------ ------------------------------- ----------------------------------- ---------------------
  **India**                 1.84                                       0.69                                       73--143                         41--56                              39--57%

  **Campaign States**       2.77                                       0.76                                       63--111                         38--44                              40--60%

  **Girls**                 3.63                                       0.88                                       31--61                          16--21                              34--52%

  **Boys**                  2.05                                       0.63                                       32--50                          22--23                              46--69%

  **Non-campaign States**   0.66                                       0.53                                       10--32                          3--12                               30--38%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are ordinary least-squares regressions models adjusted for time fixed effects and time interactions. The expected rates were extrapolated by extending the pre-intervention trend to the end of the time series and then applied to the estimated UN live births at 2013 to estimate the potential magnitude of the intervention effects. National estimates are derived from the summation of stratified models. The range represents the upper and lower bounds on the basis of one or more physician coding including family reporting the child to have a history of measles (using the local language term) and only one or more physician coding, respectively.

Discussion {#s3}
==========

The measles vaccine has high *efficacy*, preventing infection and death in 90--95% of children who receive two doses ([@bib12]; [@bib29]). However, evidence for vaccine *effectiveness* in low- and middle-income countries is more limited. Evidence of effectiveness at the population level is particularly required to counter scientific skepticism and waning public confidence in government immunization programs in India ([@bib10]; [@bib23]; [@bib22]). Our first ever quantification of the impact of national mass measles immunization campaign in a high-burden country using direct cause-specific data finds high effectiveness of measles vaccination programs in reducing child measles deaths in India.

Our direct estimates of 41,000--56,000 measles deaths averted are consistent with modeled estimates documenting approximately 66,000 under-five child deaths averted ([@bib39]). However, direct data are a far more robust form of evidence. We document 24,000 measles deaths in 2013 using a broad case definition that included family reporting of history of measles. WHO estimated 49,000 measles deaths in 2015 using a definition of either clinician-suspected measles infection or a diagnosis of fever with rash and cough, runny nose, or red eyes ([@bib43]; [@bib42]). The addition of possible measles deaths with rash and fever to our original case definition raised the estimate of measles deaths in 2013 from 24,000 to 46,000. At our observed rate of decline, we would expect 35,000 deaths in 2015 using the WHO definition. Further investigation of the reasons for these differences in total deaths from measles, particularly at the subnational level, is required. [@bib9] documented 7,000 measles deaths in 2015 using a narrower case definition that excluded a history of measles and where all deaths were so assigned by dual physician coding with final adjudication by a third senior physician if needed. Thus, substantial downward revisions of WHO modeled estimates are likely needed. The relationship between measles cases and deaths in India is also uncertain, given that WHO incidence estimates are inconsistent with documented case fatality rates in India which range from 0.8--1.4% ([@bib34]; [@bib39]; [@bib40]; [@bib42]; [@bib44]; [@bib30]). Our direct data should help to redefine current estimates of measles mortality and number of infections in India.

Could measles transmission or, at a minimum, measles deaths be eliminated in India? Drastic declines in child measles mortality suggest that elimination of measles deaths in India is feasible, albeit difficult. Measles elimination is challenging due to its high infectivity -- each infected child can infect an additional 4--26 children in South-east Asia ([@bib12]; [@bib15]). The WHO estimated the coverage of first-dose vaccine in South-east Asia (which includes India) to be below the levels that would achieve herd immunity (85% in 2012) and stagnation of coverage in the past decade ([@bib8]; [@bib29]). Documented measles outbreaks indicate that India remains endemic to measles given suboptimal coverage, with about 3 million infants not receiving first-dose measles vaccination in 2013 ([@bib8]; [@bib16]; [@bib33]; [@bib37]). India's Integrated Disease Surveillance Program reported a decline in annual measles outbreaks during 2011--2013 but gradual increases since ([@bib28]). The Global Vaccine Action Plan for 2012--2020 and the Government of India recommend second-dose measles vaccine to achieve herd immunity at 95% coverage to eliminate measles transmission ([@bib8]). Supplementary immunization activities must be regularly scheduled to reach herd immunity and to combat resurgence ([@bib39]). Though herd immunity may be difficult to achieve, efforts to improve vaccine coverage will curtail mortality, as evident by our findings. The observed reduction in under-five measles mortality may show herd immunity in cohorts born within nine months of the campaign launch. Since 2013, 11 states in India have implemented laboratory-confirmed measles surveillance. This infrastructure provides sero-epidemiological data to facilitate diagnoses of measles, detect suspected cases, and sequence circulating measles genotypes ([@bib5]; [@bib36]; [@bib38]). High quality measles surveillance through case-based detection and direct mortality statistics such as the MDS provide valuable data to monitor measles elimination programs ([@bib5]; [@bib36]).

The measles campaign was particularly successful for girls, which saw greater absolute declines in measles mortality than boys. Though the girl-boy gap in measles mortality rates narrowed, mortality remains higher in girls, as is the case for other infectious causes of death at ages 1--59 months ([@bib9]). Persisting higher mortality rates among girls than boys may be due to lower vaccination coverage, social preference for boys, and lower levels of breastfeeding and health care access ([@bib2]; [@bib7]; [@bib9]; [@bib13]; [@bib18]; [@bib31]).

The interrupted time series design addresses potential confounding by the effects of different policies occurring at the same time as the measles campaign launch. Given that the majority of child causes of death were declining from 2000 onward, we selected unbiased control deaths comparable with the pre-intervention trends of measles, pneumonia, and diarrhoea deaths. The addition of control deaths allows for evaluation of post-intervention differences rather than single-group mean or slope differences. In stratified analysis, we tested alternate intervention time points and measles case definitions, all of which reported a consistent effect. We did not observe a change in *slope* when moving the intervention forward to 2010, likely due to fewer time points in the post-intervention trend. The observed decreased in level of measles mortality when using 2010 as the intervention year might reflect greater actual vaccine delivery.

The MDS verbal autopsy form is designed to identify all major causes of death in children with low levels of misclassification ([@bib1]; [@bib9]). The verbal autopsy form contains specific questions relating to measles (e.g. presence of rash, cough, whether the respondent reported history of measles) but cannot ascertain exposure and timing of symptoms. Thus, we tested alternate case definitions, one including family-reporting of a history of measles to capture measles-associated deaths of pneumonia or diarrhoea, and the other using only physician coding of measles deaths. We observed declines specific to the campaign, in each case definition, as opposed to no additional declines in pneumonia or diarrhoea deaths. The lack of effect in pneumonia deaths may be due to measles contributing a smaller etiologic fraction than other viral, bacterial, or fungal agents (Farrar et al., submitted). The success of the measles campaign is the increase in vaccination in campaign states to levels comparable with non-campaign states. Though the effect was smaller in non-campaign states, the introduction of second-dose measles through routine immunization in these non-campaign states also contributed to the declines in measles mortality nationally. Continued diligence in mass immunization and direct mortality monitoring are both needed to achieve elimination of measles deaths in India.

Materials and methods {#s4}
=====================

Study design {#s4-1}
------------

Most deaths in India as in most low- and middle-income countries occur at home and without medical attention, precluding complete death registration and certification ([@bib32]). Starting in 2001, the Registrar General of India (RGI) and the Centre for Global Health Research implemented the MDS in 1.3 million households within its Sample Registration System (SRS), an ongoing demographic surveillance system. Following each census, the RGI partitions India into 1 million small areas comprising 150--300 homes in either rural villages or urban census enumeration blocks. Over the ensuing decade, the SRS randomly selects and monitors several thousand units within these areas, capturing approximately 140,000 births and 46,000 deaths annually. This MDS relies on 14,268 units drawn from the 1991 and 2001 censuses ([@bib32]). Approximately 900 trained non-medical RGI surveyors conduct two semi-annual rounds of interviews of household members or close associates of those who died in the preceding round. The interview uses a modified version of the 2011 WHO verbal autopsy questionnaire to capture death events and their chronology through structured checklist questions about key symptoms and a local language narrative. Each field report is randomly assigned to two of 404 trained physicians ([@bib19]), who classify the underlying causes of death according to the *International Classification of Diseases, Tenth Revision* (ICD-10; [Table 5](#table5){ref-type="table"}) ([@bib17]; [@bib41]). Coding differences are resolved by both physicians who anonymously receive the other's case notes. One of 40 senior physicians adjudicates persisting differences ([@bib1]). Details of the quality assurance checks have been published earlier ([@bib1]; [@bib9]; [@bib17]; [@bib19]; [@bib32]; [@bib3]). Ethics approval for the MDS was obtained from the Post Graduate Institute of Medical Research, St. John's Research Institute and St. Michael's Hospital, Toronto, Ontario, Canada. Consent procedures have been published earlier ([@bib11]; [@bib17]; [@bib32]).
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###### ICD-10 codes used to define measles and other causes of death.

  Disease                         ICD-10 code range
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Measles**                     B01, B05
  **Diarrhoea**                   A00-A09
  **Pneumonia**                   A37, H65-H68, H70, H71, J00-J06, J09-J18, J20-J22, J32, J36, J85, J86, P23, U04
  **Injuries**                    S00-S99, T00-T71, T73-T75, T78-T98, V01-V06, V09-V99, W00-W46, W49-W60, W64-W70, W73-W81, W83-W94, W99, X00-X06, X08-X52, X57-X99, Y00-Y36, Y40-Y66, Y69-Y91, Y97, Y98
  **Congenital anomalies**        Q00-Q07, Q10-Q18, Q20-Q28, Q30-Q45, Q50-Q56, Q60-Q87, Q89-Q93, Q95, Q96-Q99
  **Non-communicable diseases**   C00-C26, C30-C34, C37-C41, C43-C58, C60-C85, C88, C90-C97, D01-D07, D09-D48, D55-D77, D80-D84, D86, D89, E03-E07, E10-E16, E20-E32, E34, E35, E65-E68, E70-E80, E83-E90, F00-F07, F09-F25, F28-F34, F38-F45, F48, F50-F55, F59-F66, F68-F73, F78-F84, F88-F95, F98, F99, G10-G13, G20-G26, G30-G32, G35-G37, G40, G41, G43-G47, G50-G64, G70-G73, G80-G83, G90-G99, H00-H06, H11, H13, H15-H22, H25-H28, H30-H36, H40 H42, H43-H55, H57-H59, H61, H62, H69, H72-H75, H80-H83, H90-H95, I00-I02, I05-I13, I15, I20-I28, I31, I34-I38, I42-I52, I60-I74, I77-I89,I95, I97-I99, J30, J31, J33-J35, J37-J47, J60, J64, J66-J70, J80-J82,J84, J90-J96, J98, J99, K00, K03, K06-K14, K20-K23, K25-K31,K35-K38, K40-K46, K50-K52, K55-K60, K62, K63, K70-K77, K80, K82, K83, K85-K87, K90-K93, L05, L10-L14, L20-L30, L40-L45, L50-L60, L62-L68, L70-L75, L80-L95, L97-L99, M02, M03, M05-M25, M30-M36, M40-M43, M45-M51, M53, M54, M61-M63, M65-M68, M70-M73,M75-M77, M79-M85, M87-M96, M99, N00-N08, N11-N23, N25-N29,N31-N33, N35-N37, N39, N40, N42-N48, N50, N51, N60, N62-N64, N75-N77, N80-N99, P04, P08, P51, P53-P60, P70-P72, P74-P76, P78, P80, P81, P83, P92-P94, R00, R01, R03-R05, R06, R11-R23, R26, R27, R29-R36, R39-R49, R55, R56, R59, R63, R70-R74, R76, R77, R80-R82, R84-R87, R90, R91

The measles case definition attributed a death to measles if at least one physician coded measles as the cause of death; or that the living respondent reported the child to have a history of measles (using the local language term. Control deaths were final codes of injury, non-communicable disease, or congenital anomaly.

Mortality rate calculations {#s4-2}
---------------------------

The main outcome was 1--59 month measles mortality using a case definition that required at least one physician reviewer of the verbal autopsy to code measles (ICD-10 codes B01 or B05) as the cause of death or that the living respondent reporting a measles death noted a history of measles (using the local language term) ([Table 5](#table5){ref-type="table"}). Though the campaign targeted children from 9 months to 10 years of age, our analysis focuses on children aged 1--59 months who comprised 84% (1638/1958) of these deaths. We applied proportions of measles deaths to all-causes among 1--59 month children and calculated three-year moving averages weighted by SRS sampling probabilities for the 35 Indian states or territories. We applied these weighted proportions to live births and deaths for India at the national and state level (derived from SRS vital statistics and census data) and adjusted to match the national birth totals from the UN Population Division and death totals from UN Population Division's Inter-agency Group for Child Mortality Estimation ([@bib9]). We calculated rates for each six-month period as death counts were too low to separate into monthly data as semi-annual rates correspond to the frequency of survey collection conducted in the MDS.

Interrupted time series analysis {#s4-3}
--------------------------------

We conducted a multiple-group interrupted time series to assess the impact of measles campaign on 1--59 month measles mortality reduction. We arranged the data in a time series and divided the sample into time periods before and after campaign launch ([@bib27]). We used log transformed rates to account for potential nonlinearity. We calculated the average annual rate of reduction by India and by state using the linear association between log rate and time ([@bib35]). We fitted the data using ordinary least squares linear segmented regression ([@bib24]). As control deaths, we used injuries, congenital anomalies, and non-communicable diseases, each having ICD-10 code groupings as detailed in [Table 5](#table5){ref-type="table"} ([@bib9]). We selected various control groups by comparing their pre-intervention trends to that of measles, pneumonia, and diarrhoea ([@bib24]). Control selection used a matching framework to match control deaths to our measles, pneumonia, or diarrhoea deaths based on balancing of the pre-intervention trend characteristics ([@bib25]). The pre-intervention trends excluding 2009 deaths did not differ from control deaths (p=0.9). We assessed model validity by visual inspection of autocorrelation/partial autocorrelation functions and residuals. We stratified models by age groups, sex, and campaign states. In sensitivity analysis, we fitted additional models using alternate case definitions and intervention time points.

Multilevel logistic regression analysis {#s4-4}
---------------------------------------

We used multilevel logistic regression to examine characteristics of health-seeking behavior associated with measles mortality ([@bib21]). We organized the data into a three-level hierarchical structure consisting of children (first level) nested within districts (second level) nested within states (third level). We fitted random intercepts at the district and state level to account for regional variation. The predictors considered were: age at death, sex, year of birth, and residence in a measles campaign district. We also adjusted for state-level coverage estimates of measles vaccination (defined in the National Family Health Survey and the District Level Household and Facility Survey as the percentage of children aged 12 to 23 months receiving any measles vaccine from routine immunization), vitamin A supplementation, oral rehydration supplementation, maternal literacy, and treatment-seeking for diarrhoea and pneumonia. We obtained the coverage data from Indian national surveys corresponding to our study period including the Government of India's District Level Household Surveys (DLHS; 2002--2004, 2007--2008 and 2011--2012) and National Family Health Surveys (NFHS; 2005--2006, and 2013--2014). Using these coverage indicators, we conducted a difference-in-differences analysis assessing the change in coverage indicators before and after campaign launch in campaign states versus non-campaign states. We report measures of association as odds ratios (ORs; including 99% confidence intervals). We use area-level variances, median odds ratios, and intra-class correlations as measures of variation ([Table 6](#table6){ref-type="table"}) ([@bib21]).
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###### Multilevel models for measles mortality among 1--59-month children, India, 2005--2013.

  N = 26,505                                      Model 1       Model 2             Model 3             Model 4             Model 5             Model 6
  ----------------------------------------------- ------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Level 1 (Individual/Child)**                                                                                                                
  12--59 months (v. 1--11 months)                 \-\--         1.50 (1.34, 1.69)   \-\--               \-\--               1.56 (1.38, 1.75)   1.48 (1.33, 1.42)
  Female (v. Male)                                \-\--         1.28 (1.16, 1.42)   \-\--               \-\--               1.28 (1.15, 1.41)   1.28 (1.15, 1.42)
  Born ≥ 2009 (v. \< 2009)                        \-\--         0.74 (0.66, 0.84)   \-\--               \-\--               0.80 (0.70, 0.91)   0.80 (0.70, 0.91)
  Rural (v. Urban)                                \-\--         1.04 (0.89, 1.21)   \-\--               \-\--               1.05 (0.90, 1.22)   1.04 (0.89, 1.21)
  Antibiotics (v. No)                             \-\--         1.15 (0.96, 1.38)   \-\--               \-\--               1.14 (0.95, 1.37)   \-\--
  Missing/Unknown                                 \-\--         0.89 (0.76, 1.04)   \-\--               \-\--               0.88 (0.75, 1.03)   \-\--
  Received at Least One Measles Vaccine (v. No)   \-\--         1.03 (0.91, 1.15)   \-\--               \-\--               1.03 (0.92, 1.16)   \-\--
  Missing/Unknown                                 \-\--         0.87 (0.73, 1.03)   \-\--               \-\--               0.87 (0.75, 1.03)   \-\--
  **Level 2 (District)**                                                                                                                        
  Living in Measles Campaign District (v. No)     \-\--         \-\--               0.54 (0.39, 0.75)   \-\--               0.57 (0.40, 0.80)   0.57 (0.40, 0.80)
  **Level 3 (State)**                                                                                                                           
  Measles Vaccination (%)                         \-\--         \-\--               \-\--               0.97 (0.94, 1.00)   0.96 (0.92, 0.99)   0.96 (0.92, 0.99)
  Vitamin A Supplementation (%)                   \-\--         \-\--               \-\--               0.99 (0.97, 1.02)   0.99 (0.97, 1.01)   0.99 (0.97, 1.01)
  Oral Rehydration Supplementation (%)            \-\--         \-\--               \-\--               0.97 (0.94, 0.99)   0.97 (0.94, 0.99)   0.97 (0.94, 0.99)
  Maternal Literacy (%)                           \-\--         \-\--               \-\--               0.97 (0.94, 0.99)   0.97 (0.95, 1.00)   0.97 (0.95, 1.00)
  Diarrhoea Treatment-seeking (%)                 \-\--         \-\--               \-\--               1.00 (0.99, 1.03)   1.01 (0.98, 1.03)   1.00 (0.98, 1.03)
  Pneumonia Treatment-seeking (%)                 \-\--         \-\--               \-\--               1.06 (1.02, 1.10)   1.07 (1.02, 1.11)   1.07 (1.02, 1.11)
  **Measures of Variation**                                                                                                                     
  **Area-level Variance (SE)**                                                                                                                  
  District                                        0.09 (0.03)   0.14 (0.05)         0.09 (0.03)         0.07 (0.03)         0.07 (0.03)         0.07 (0.03)
  State                                           0.15 (0.06)   0.09 (0.03)         0.16 (0.06)         0.15 (0.06)         0.15 (0.06)         0.14 (0.07)
  **Median Odds Ratio**                                                                                                                         
  District                                        1.34          1.34                1.34                1.44                1.28                1.28
  State                                           1.44          1.42                1.46                1.30                1.44                1.43
  **Intra-class Correlation (%)**                                                                                                               
  District                                        6.83          6.46                7.02                6.33                6.10                5.99
  State                                           4.17          3.83                4.39                4.28                4.14                4.06

All models are fitted with random intercepts at the district and state level. Model 1 is a null model containing no predictors in order to assess variance and clustering. Model 2 includes only individual-level characteristics. Models 3 and 4 include only district- and state-level predictors, respectively. Model 5 includes all predictors. Model 6 includes only the relevant predictors from the previous model.

Geographical distribution of measles mortality risk {#s4-5}
---------------------------------------------------

We constructed maps of 1--59 month measles mortality to determine the geographical distribution of measles mortality risk in India. We fitted the data using a generalized linear geostatistical model with integrated nested Laplace approximations. We adjusted for populations living in measles campaign districts and urban/rural residence. We used R version 3.5.1 for mapping.

Mortality impact {#s4-6}
----------------

To estimate the magnitude of the intervention, we derived cumulative deaths differences using observed and expected measles mortality rates from the interrupted time series model. We extrapolated the expected rates using the pre-intervention trend from campaign launch to the end of the time series. We applied UN live births to their respective year and summed for the 2010--2013 period, then calculated deaths averted and percent averted between the observed deaths and the expected deaths. We report upper and lower bounds using the broad case definition, which captures one physician coding measles or family reporting of a history of measles, and the narrow case definitions, which captures only one physician coding measles. We used Stata version 15 for statistical analysis.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The impact of measles immunization campaigns in India using a nationally representative sample of 27,000 child deaths\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Mark Jit as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen Eduardo Franco as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity:; Narendra Arora (Reviewer \#2); Anindya Bose (Reviewer \#3).

The reviewers all agreed that this is an important paper, using a large and rich dataset to demonstrate the strong impact of measles SIAs in India, as well as yielding a lot of valuable insights about measles epidemiology in that country. Overall, we would like to see this paper published, but there are a few aspects of the analysis and results that need some explanation.

1\) The analysis was limited to measles in children under 5 years. Some commentary on the appropriateness of this would be useful, since the target age range for the SIAs was up to 10 years. What% of measles deaths are in \>5s -- these might be particularly important in better performing states and hence may make the highest burden states look worse than they are in comparison.

2\) Figure 2: The interrupted time-series with non-measles controls is not very convincing because even the non-campaign states experience a much faster decline in measles deaths than control deaths. This suggests that measles mortality is decreasing faster overall than mortality due to the control diseases, and a difference-in-difference analysis is more reliable.

3\) Given the temporary and likely artifactual rise in measles mortality reported in 2009 (subsection" Interrupted Time Series Analysis": believed due to an increase in reporting rather than actual deaths), was this year also be taken out of the other analyses e.g. those in Table 1, Table 2 and Figure 1? Otherwise it may cause the downward slope of the pre-SIA trend to be underestimated. This is particularly important in the analysis in Table 2 which is used to calculate the overall measles deaths prevented.

4\) The Discussion section shows that WHO estimates of measles mortality in India are much higher than those estimated from MDS data. This is quite an important statement and if true may imply that there are shortcomings in the WHO methodology that may require revisiting measles mortality estimates in other countries also. Could this be explored a bit further e.g. what are the differences in WHO methodology that may have led to this difference?

5\) In Table 2, figures indicating the pre and post campaign state would be useful in interpretation at state level.

6\) In subsection "Coverage of Measles Immunization and Related Health Indicators", source of the measles coverage data and whether for one dose or two doses needs to be specified.

7\) The MSL campaign starting 2010 targeted 9 months -10 years age group. This article purports to show that the campaign had an impact on measles deaths in 1-59 month old children in 2009/2010 to 2013. However, the cohort that was \<9 months old in 2010, 1 year old in 2011, \<2 years old in 2012, \<3 years old in 2013 etc. would not have received any vaccination though SIA. So the effects of the campaign observed in this age group would be the indirect effect of the campaign by reducing transmission through sudden increase of herd immunity in cohorts born from 9 months before start of campaign. This indirect effect should be mentioned when we ascribe impact on mortality to immunization delivered through the campaign. This could also be the key underlying epidemiological mechanism in campaign states vs. non-campaign states where no such sudden increase in herd immunity occurred.

8\) Cause of death ascertainment from measles should not have taken MCV vaccination status into account. This should be mentioned explicitly as this can introduce a bias in the results.

One of the reviewers pointed out that there is now a measles technical advisory group in India. Hence it may be appropriate to share this paper with them, with the Ministry of Health India and with WHO SEARO office, given the interest in the subject by these groups.
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Author response

> 1\) The analysis was limited to measles in children under 5 years. Some commentary on the appropriateness of this would be useful, since the target age range for the SIAs was up to 10 years. What% of measles deaths are in \>5s -- these might be particularly important in better performing states and hence may make the highest burden states look worse than they are in comparison.

Measles deaths among children aged 1--59 months comprised 84% (1638/1958) of children up to 10 years of age in our overall sample. This proportion did not differ greatly between states. We have added the following to the Materials and methods section:

"Though the campaign targeted children up to 10 years of age, our analysis focuses on children aged 1-59 months who comprised 84% (1638/1958) of these deaths."

> 2\) Figure 2: The interrupted time-series with non-measles controls is not very convincing because even the non-campaign states experience a much faster decline in measles deaths than control deaths. This suggests that measles mortality is decreasing faster overall than mortality due to the control diseases, and a difference-in-difference analysis is more reliable.

We agree that, visually, the measles mortality rate appears to decline faster than control mortality rates in non-campaign states. Using the interrupted time series model, we adjusted for differences in the baseline mean and time trends between measles and control mortality. Measles mortality in campaign states saw a significant decline after campaign launch (P = 0.040), whereas measles mortality in non-campaign states did not change after campaign launch (P = 0.157).

We agree that to evaluate change in measles mortality following the intervention, the trends in measles and control mortality prior to the intervention must be parallel. For all models, we compared the pre-intervention trends in measles deaths to that of control deaths and found no significant differences. We have added the results of the pre-intervention trend comparisons to the footnotes in Figure 2 and Figure 4.

Figure 2: "We observed no significant difference when comparing pre-intervention trends for the control deaths to the deaths from measles, pneumonia, or diarrhoea in the campaign states, or to measles deaths in the non-campaign states (P \> 0.1 for all four comparisons)."

Figure 4: "We observed no significant difference when comparing pre-intervention trends for the control deaths to those for case deaths based on the narrower definitions of at least one physician coding measles and both physicians coding measles (P \> 0.4 for both comparisons)."

> 3\) Given the temporary and likely artifactual rise in measles mortality reported in 2009 (subsection" Interrupted Time Series Analysis": believed due to an increase in reporting rather than actual deaths), was this year also be taken out of the other analyses e.g. those in Table 1, Table 2 and Figure 1? Otherwise it may cause the downward slope of the pre-SIA trend to be underestimated. This is particularly important in the analysis in Table 2 which is used to calculate the overall measles deaths prevented.

We understand the concern for potential underestimation of the pre-intervention trends. We were cautious to ensure the estimates are conservative. We tested removal of the temporary rise in measles mortality in 2009 and saw no difference in pre-intervention slopes (P = 0.891). The narrower case definitions did not show a rise in measles mortality in 2009 as they did not include family-reporting of measles history. For these more narrow definitions, pre-intervention trends in measles deaths and control deaths did not differ significantly (see reply to Comment \#2 above). We updated the Materials and methods section as follows:

"The pre-intervention trends excluding 2009 deaths did not differ from control deaths (P = 0.9)."

> 4\) The Discussion section shows that WHO estimates of measles mortality in India are much higher than those estimated from MDS data. This is quite an important statement and if true may imply that there are shortcomings in the WHO methodology that may require revisiting measles mortality estimates in other countries also. Could this be explored a bit further e.g. what are the differences in WHO methodology that may have led to this difference?

Thank you for raising this important point. Our measles case definition differs from the WHO definition which relies on either clinician-suspected measles infection or a diagnosis of fever with rash and cough, runny nose, or red eyes (<https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_11_Measles_R2.pdf>). We updated the Discussion section as follows:

"WHO estimated 49,000 measles deaths in 2015 using a definition of either clinician-suspected measles infection or a diagnosis of fever with rash and cough, runny nose, or red eyes (World Health Organization, 2018a, 2016). The addition of possible measles deaths with rash and fever to our original case definition raised the estimate of measles deaths in 2013 from 24,000 to 46,000. At our observed rate of decline, we would expect 35,000 deaths in 2015 using the WHO definition. Further investigation of the reasons for these differences in total deaths from measles, particularly at the subnational level, is required."

> 5\) In Table 2, figures indicating the pre and post campaign state would be useful in interpretation at state level.

We are not able to reliably estimate AARR by pre- and post-intervention time periods by state due to low numbers. We updated now Table 2 to include AARR estimates for large states in India and by campaign/non-campaign states. We also added pre-intervention and post-intervention AARRs by campaign and non-campaign states to the footnotes. We updated Figure 1 to include pre- and post-intervention AARRs by sex, campaign states, and urban/rural residence, and India overall.

> 6\) In subsection "Coverage of Measles Immunization and Related Health Indicators", source of the measles coverage data and whether for one dose or two doses needs to be specified.

To clarify the data sources and measles coverage definition in the *eLife* format, we added the definition of measles vaccination coverage to the Results section, Materials and methods section and relevant figures as follows:

Results section: "National measles immunization coverage (defined as the percentage of children aged 12 to 23 months receiving any dose of measles vaccine) improved from 2002--2014, particularly in campaign states (Figure 5)."

Materials and methods section: "We also adjusted for state-level coverage estimates of measles vaccination (defined in the National Family Health Survey and the District Level Household and Facility Survey as the percentage of children aged 12 to 23 months receiving any measles vaccine), vitamin A supplementation, oral rehydration supplementation, maternal literacy, and treatment-seeking for diarrhoea and pneumonia."

Figure 5: "Estimates were obtained from the National Family Health Survey and the District Level Household and Facility Survey through 2002 to 2014. Measles vaccination coverage was defined as the percentage of children aged 12 to 23 months receiving any measles vaccine."

> 7\) The MSL campaign starting 2010 targeted 9 months -10 years age group. This article purports to show that the campaign had an impact on measles deaths in 1-59 month old children in 2009/2010 to 2013. However, the cohort that was \<9 months old in 2010, 1 year old in 2011, \<2 years old in 2012, \<3 years old in 2013 etc. would not have received any vaccination though SIA. So the effects of the campaign observed in this age group would be the indirect effect of the campaign by reducing transmission through sudden increase of herd immunity in cohorts born from 9 months before start of campaign. This indirect effect should be mentioned when we ascribe impact on mortality to immunization delivered through the campaign. This could also be the key underlying epidemiological mechanism in campaign states vs. non-campaign states where no such sudden increase in herd immunity occurred.

We have updated the Discussion section as follows:

"The observed reduction in under-five measles mortality may show herd immunity in cohorts born within nine months of the campaign launch."

> 8\) Cause of death ascertainment from measles should not have taken MCV vaccination status into account. This should be mentioned explicitly as this can introduce a bias in the results.

The proportion of respondents reporting no measles vaccination when both physicians assigned measles as the cause of death was 50% and did not differ greatly with the broader case definitions and controls (Table 1---source data 1). We updated the Results section as follows:

"Despite inherent misclassification that can be expected from verbal autopsies, we observed that the proportion vaccinated against measles did not differ across case definitions, suggesting that physician assignment of deaths was not unduly biased by a history of measles vaccination (See source data for Table 1)."

> One of the reviewers pointed out that there is now a measles technical advisory group in India. Hence it may be appropriate to share this paper with them, with the Ministry of Health India and with WHO SEARO office, given the interest in the subject by these groups.

Thank you. We are in collaboration with the Indian Council of Medical Research and have shared preliminary results. We will be holding dissemination sessions with collaborators and relevant organizations, in addition to working with the WHO on validation of national and subnational estimates.
